Keros Therapeutics, Inc. reported a net income of $148.5 million for the first quarter of 2025, a significant increase compared to a net loss of $43.1 million in the first quarter of 2024. This substantial improvement was largely due to revenue recognized from the company's license agreement with Takeda Pharmaceuticals U.S.A., Inc.
Research and development expenses for the first quarter of 2025 were $48.7 million, up from $38.3 million in the same period of 2024, reflecting continued investment in pipeline advancement. General and administrative expenses saw a minor increase to $10.5 million from $10.3 million.
As of March 31, 2025, Keros held a robust cash and cash equivalents balance of $720.5 million, up from $559.9 million at the end of 2024. Based on current operating assumptions, the company expects this capital to fund its operating expenses and capital expenditure requirements into 2029.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.